#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15062	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2178	689.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1785	1785	T	842	T	785	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15062	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2178	689.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1519	1519	C	897	C	839	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15062	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2178	689.1	0	HET	.	.	.	A69G	.	69	69	A	404	404	A	865	A,G	480,330	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27530	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3450	794.2	0	.	n	.	0	C1176T	SNP	1176	1176	C	1483	1483	T	827	T,C	783,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27530	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3450	794.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1644	1644	A	989	A	915	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27530	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3450	794.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2278	2278	C	869	C	799	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27530	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3450	794.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2352	2352	A	918	A	853	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27530	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3450	794.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2904	2904	C	848	C	780	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	22	blaTEM	861	349	100.0	blaTEM.l15.c30.ctg.1	349	1.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	0	22	blaTEM	861	288	100.0	blaTEM.l15.c30.ctg.2	326	2.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	1864	folP	852	852	99.88	folP.l15.c17.ctg.1	1435	129.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	716	718	AAA	196;194;193	A,G;A;A	180,1;180;178	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	1864	folP	852	852	99.88	folP.l15.c17.ctg.1	1435	129.0	1	SNP	p	R228S	1	.	.	682	684	AGC	947	949	AGC	173;172;174	A;G;C	165;164;163	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5056	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3309	152.0	0	.	p	.	0	K261del	DEL	781	781	A	1046	1046	A	152	A	138	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5056	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3309	152.0	1	SNP	p	S91F	0	.	.	271	273	TCC	536	538	TCC	184;186;186	T;C,T;C	168;170,1;170	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5056	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3309	152.0	1	SNP	p	D95N	0	.	.	283	285	GAC	548	550	GAC	190;191;192	G;A,G;C	176;173,1;179	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5056	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3309	152.0	1	SNP	p	D95G	0	.	.	283	285	GAC	548	550	GAC	190;191;192	G;A,G;C	176;173,1;179	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1502	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1356	110.6	1	SNP	p	G45D	0	.	.	133	135	GGC	481	483	GGC	197;197;199	G;G,A;C	177;172,1;174	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	792	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1034	76.3	0	.	n	.	0	A197.	DEL	197	197	A	568	568	A	189	A	177	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5694	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2899	195.6	1	SNP	p	D86N	0	.	.	256	258	GAC	551	553	GAC	237;237;237	G;A;C	219;214;218	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5694	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2899	195.6	1	SNP	p	S87I	0	.	.	259	261	AGT	554	556	AGT	236;234;236	A;G;T	215;213;215	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5694	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2899	195.6	1	SNP	p	S87R	0	.	.	259	261	AGT	554	556	AGT	236;234;236	A;G;T	215;213;215	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5694	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2899	195.6	1	SNP	p	S87W	0	.	.	259	261	AGT	554	556	AGT	236;234;236	A;G;T	215;213;215	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5694	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2899	195.6	1	SNP	p	S88P	0	.	.	262	264	TCC	557	559	TCC	234;232;230	T;C;C	213;210;211	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4048	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2544	158.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1507	1509	GGC	168;164;164	G;G;C	157;156;153	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1219	1221	GCA	201;201;202	G;C;A	183;182;186	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1222	1224	ATC	203;204;205	A;T;C	185;184;186	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1234	1236	GTG	207;210;210	G;T;G	186;187;187	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1234	1236	GTG	207;210;210	G;T;G	186;187;187	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1738	1740	ACC	177;174;175	A;C;C	160;158;161	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1792	1794	GCG	176;175;172	G;C;G	153;134;140	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1792	1794	GCG	176;175;172	G;C;G	153;134;140	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1915	1917	GGC	166;165;165	G;G;C	154;151;153	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1924	1926	GGC	170;167;167	G;G;C	154;153;154	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	159.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1942	1944	CTG	164;162;165	C,G;T;G	112,8;104;125	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6044	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2980	202.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1574	1576	CCG	214;212;211	C;C;G	187;188;186	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2092	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1821	114.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	574	574	C	170	C	159	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	481	483	GAA	253;253;254	G;A;A	237;240;241	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	769	771	GAT	270;269;271	G;A;T	249;249;249	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	892	894	TCA	251;250;251	T;C;A	232;230;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	D212N	NONSYN	634	636	GAT	1003	1005	AAT	230;229;230	A,G;A;T	217,1;219;216	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1021	1023	GTC	238;240;239	G;T,C;C	226;228,1;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1033	1035	TCT	242;235;239	T;C;T	230;229;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1351	1353	GCA	217;216;220	G;C;A	202;201;200	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	1	SNP	p	G120K	1	.	.	358	360	AAG	727	729	AAG	251;248;254	A;A;G	236;235;239	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	1	SNP	p	A121D	1	.	.	361	363	GAC	730	732	GAC	255;256;253	G;A;C	241;240;237	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2980	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1560	190.3	1	SNP	p	D121N	0	.	.	361	363	GAC	730	732	GAC	255;256;253	G;A;C	241;240;237	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11218	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4736	236.0	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1948	1950	AAT	233;233;231	A,C;A;T	217,1;217;219	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1098	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1129	96.8	1	SNP	p	V57M	1	.	.	169	171	ATG	554	556	ATG	246;254;253	A;T;G,A	227;230;229,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
